MMP9 and cancer: Tumor-infiltrating lymphocytes (TILs) were found to be strictly bound to the efficacy of immune-based treatments [25], while neutrophils release vascular endothelial growth factor (VEGF), matrix metalloproteinase 9 (MMP-9), and other cytokines which impact the compositions and molecular interactions of the microenvironment of tumors [26,27], while platelets interact with cancer cells, protecting them from immune surveillance [28].